Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31
2019
PURPOSERecent trials have shown potential benefit of extended adjuvant endocrine therapy and relatively high risk of recurrence (RoR) after 5 years in hormone receptor-positive (HR+) human epiderma...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
21
References
20
Citations
NaN
KQI